Biosimilar Pharmaceuticals
"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
| Descriptor ID |
D059451
|
| MeSH Number(s) |
D20.215.261
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".
This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in this website by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 0 | 3 |
| 2018 | 5 | 0 | 5 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.
-
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Mar; 42(3):1360-1392.
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
-
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
-
A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body. Immunotherapy. 2023 12; 15(18):1501-1509.
-
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease. Immunotherapy. 2022 12; 14(17):1353-1359.
-
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
-
Use of Biosimilar Medications in Oncology. JCO Oncol Pract. 2022 Mar; 18(3):177-186.
-
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.
-
Biosimilars for the Treatment of Retinal Diseases. Ophthalmic Surg Lasers Imaging Retina. 2021 05; 52(5):242-246.